US Foods Reaffirms Fiscal Year 2025 Guidance
Company to Participate at the 2026 ICR Conference ROSEMONT, Ill.–(BUSINESS WIRE)–US Foods Holding Corp. (NYSE: USFD) announced today that it is reaffirming... Read more.
J.Jill, Inc. Raises Fourth Quarter Guidance Ahead of the 28th Annual ICR Conference
QUINCY, Mass.–(BUSINESS WIRE)–J.Jill, Inc. (NYSE:JILL) today raised its fourth quarter fiscal 2025 guidance in advance of its fireside chat and investor... Read more.
ShareBuilder 401k Empowers the Self-Employed With Free Solo 401(k) Setup to Start the New Year
Leading digital provider waives setup costs for “companies of one” from January 12 through February 4 to help solopreneurs maximize tax savings for 2025 and... Read more.
CitiTrends Announces 2025 Holiday Sales Results
Total Holiday Sales for the nine-week period ending January 3, 2026 of $191.2 million, an increase of 9.6% to last year Comparable store sales growth of 9.3%; Two-year... Read more.
Spire Global Successfully Launches 9 Satellites on SpaceX’s Twilight Mission
Launch includes next-generation hyperspectral microwave sounder to advance global weather forecasting VIENNA, Va.–(BUSINESS WIRE)–Spire Global, Inc.... Read more.
Zura Bio Reports Business Updates and Outlook for 2026
2026 begins as a transformative year for Zura with potential clinical validation of tibulizumab as a groundbreaking therapy in hidradenitis suppurativa (HS) Expanded... Read more.
lululemon athletica inc. Updates Revenue and Earnings Expectations for the Fourth Quarter Ahead of the ICR Conference
VANCOUVER, British Columbia–(BUSINESS WIRE)–lululemon athletica inc. (NASDAQ:LULU) today announced that the Company now expects net revenue and diluted... Read more.
Babcock & Wilcox to Participate in the 28th Annual Needham Growth Conference on January 16, 2026
AKRON, Ohio–(BUSINESS WIRE)–$BW–Babcock & Wilcox Enterprises, Inc. (“B&W” or the “Company”) (NYSE: BW) a leader... Read more.
WEX Advances Multi-Year Board Refreshment Plan
David Foss Appointed as Vice Chair and Lead Independent Director, Effective as of the Company’s 2026 Annual Meeting of Stockholders Shikhar Ghosh and Jack VanWoerkom... Read more.
Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC)
Summit to Advance Development Opportunities of Ivonescimab with GSK’s Novel B7-H3 risvutatug rezetecan Multiple Solid Tumor Settings to Be Pursued with Clinical... Read more.